Prevention of NAFLD and CVD Through Lifestyle Intervention

Recruiting now · Not applicable

Conditions studied: Non-Alcoholic Fatty Liver Disease, Gallstone Disease

In brief

Prevention of non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) through lifestyle intervention (MAUCO+) is a clinical trial that aims to improve sarcopenia, aerobic capacity, body composition, and lipid profile, insulin resistance, cardiovascular risk, NAFLD, and maintain a healthier lifestyle. Through the implementation of physical activity and nutritional programs.

Key facts

Study ID

NCT05618626

Run by

Pontificia Universidad Catolica de Chile

People needed

300

Starts

2021-09-27

Expected to finish

2025-04-30

Last updated by the study team

2024-11-19

Who can join

Age: 45 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• With and without gallstones disease
• With various degrees of NAFLD (none too severe)

You may not qualify if…

• Any significant comorbidity or physical limitation to undergo resistance exercise program
• Use of medications that alter muscle mass (e.g., corticosteroids)
• History of hepatitis B or C
• Use of hepatotoxic drugs

Where it is running

• Centro MAUCO+ — Molina, Maule Region, Chile (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.